TRVI Stock Forecast & Price Target

Trevi Therapeutics, Inc. is positioned favorably due to the significant efficacy of its investigational therapy, Haduvio, which demonstrated a 56% reduction in chronic cough compared to placebo in its Phase 2a RIVER trial, significantly outperforming the 34% reduction seen with its competitor, camlipixant. The company's successful alignment with the FDA on its Phase 3 development program underscores confidence in Haduvio's potential market entry for idiopathic pulmonary fibrosis (IPF)-related chronic cough, with strategic execution of multiple clinical trials underway. Additionally, Trevi's fourth-quarter financial performance showed a reduced net loss and strengthened balance sheet, providing a solid foundation for ongoing clinical development without near-term financing concerns.

Trevi Therapeutics is facing significant financial challenges, highlighted by a net loss of $42.8 million in fiscal year 2025, indicating ongoing operational difficulties amid high development costs. The company's cash position of $188.3 million may not suffice to cover escalating expenses associated with the clinical development of its investigational therapy, Haduvio. Additionally, the reduced research and development spending, despite a disappointing fourth-quarter loss of $8.3 million, points to potential strain in sustaining its clinical programs.